CTOs on the Move

Catalent

www.catalent.com

 
Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. Catalent develops. With our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. Catalent delivers. As the world leader in ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.catalent.com
  • 14 Schoolhouse Road
    Somerset, NJ USA 08873
  • Phone: 877.587.1835

Executives

Name Title Contact Details
Veda Walcott
VP, Quality, Biologics & Global Regulatory Affairs Profile
Charles Lickfold
Senior Vice President and Chief Information Officer Profile
Kay Schmidt
Senior Vice President of Technical Operations Profile
Alessandro Maselli
President and Chief Operating Officer Profile
Jody Jenkins
CISO Profile

Funding

Catalent raised $550M on 02/10/2021

Similar Companies

GuideWell

GuideWell Source is a leading administrative services company providing full-service, end-to-end business services for health plans and government sponsored health care programs.

Westminster Gardens Health Ctr

Westminster Gardens Health Ctr is a Duarte, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIOCIUS Life Sciences

BIOCIUS Life Sciences is a Wakefield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innov-X Systems

Innov-X Systems Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

StemCells

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.